Response to “Risperidone and sulpiride: Brands vs generics”
Section snippets
Conflict of interest
The authors declare no conflicts of interest.
Contributors
Chih-Wei Hsu participated in interpreting data, reviewing references, and drafting the manuscript. Sheng-Yu Lee participated in the design of the study. Liang-Jen Wang executed the statistical analysis and revised the manuscript. All authors read and approved the final manuscript and contributed to the drafting and revising of the paper.
Acknowledgements
This study is based in part on data from the NHIRD-TW provided by the National Health Insurance Administration, Ministry of Health and Welfare and managed by National Health Research Institutes (Registered number 100196). The interpretation and conclusions contained herein do not represent those of National Health Insurance Administration, Ministry of Health and Welfare or National Health Research Institutes.
Role of funding source
This study was supported by the Chang Gung Memorial Hospital Research Project (CMRPG2A0341). The funding sources had no involvement in the study design, collection, analysis and interpretation of data, writing of the report or the decision to submit the article for publication.
References (2)
- et al.
Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan
Schizophr. Res.
(2018) Risperidone and sulpiride: Brands vs generics
Schizophr. Res.
(2018)